ArticleFrontiers in oncology2025
Malignant mesothelioma in rare sites: two case reports.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesothelioma is a rare tumor originating from mesothelial cells in the pleura or other sites. Malignant pleural mesothelioma (MPM) is the most common aggressive type of mesothelioma (accounting for 81%) and carries a poor prognosis (median OS: 1 year). Diagnosing diverse histologic types is challenging. We report two cases: a 72-year-old female with peritoneal mesothelioma demonstrated a remarkable response, with the lesion shrinking from 150×160mm to radiologically undetectable after chemo-immunotherapy, resulting in a sustained complete response. Conversely, a 66-year-old male with MPM exhibited primary platinum resistance, progressing after first-line pemetrexed/lobaplatin and subsequent second-line chemotherapy. Peritoneal mesothelioma responded better to immuno-chemotherapy, while MPM showed platinum resistance. These contrasting disparate outcomes underscore that precise pathology and individualized treatment based on anatomic site are crucial, suggesting that malignant pleural and peritoneal mesothelioma may represent distinct clinical entities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.